

https://dspace.org/

Modulation of cell death and pathogenicity by eugenol tosylate congeners in Candida Albicans

Lone, Shabir Ahmad

2020
https://hdl.handle.net/10539/29949

Downloaded from a DSpace repository. https://dspace.org/

Abegg, M. A., Alabarse, P. V. G., Schüller, Á. K. & Benfato, M. S. 2012. Glutathione levels in and total antioxidant capacity of *Candida* sp. cells exposed to oxidative stress caused by hydrogen peroxide. *Revista da Sociedade Brasileira de Medicina Tropical,* 45**,** 620-626.

Abrantes, P. M. D. S., McArthur, C. P. & Africa, C. W. J. 2014. Multi-drug resistant (MDR) oral *Candida* species isolated from HIV-positive patients in South Africa and Cameroon. *Diagnostic Microbiology and Infectious Disease*, 79, 222-227.

Abrão, P. H. O., Pizi, R. B., De Souza, T. B., Silva, N. C., Fregnan, A. M., Silva, F. N., Coelho, L. F. L., Malaquias, L. C. C., Dias, A. L. T., Dias, D. F., Veloso, M. P. & Carvalho, D. T. 2015. Synthesis and biological evaluation of new eugenol Mannich bases as promising antifungal agents. *Chemical Biology & Drug Design,* 86**,** 459-465.

Africa, C. W. J. & Abrantes, P. M. D. S. 2016. *Candida* antifungal drug resistance in sub-Saharan African populations: A systematic review. *F1000Research*, 5**,** 2832.

Ahmad, A., Wani, M. Y., Khan, A., Manzoor, N. & Molepo, J. 2015. Synergistic interactions of eugenol-tosylate and its congeners with fluconazole against *Candida albicans*. *PLOS One,* 10, e0145053.

Ahmad, A., Khan, A., Akhtar, F., Yousuf, S., Xess, I., Khan, L. A. & Manzoor, N. 2011. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against *Candida*. *European Journal of Clinical Microbiology & Infectious Diseases,* 30**,** 41-50.

Ahmad, A., Khan, A., Manzoor, N. & Khan, L. A. 2010. Evolution of ergosterol biosynthesis inhibitors as fungicidal against *Candida*. *Microbial Pathogenesis,* 48**,** 35-41.

Ahmad, A., Molepo, J. & Patel, M. 2016. Challenges in the development of antifungal agents against *Candida*: Scope of phytochemical research. *Current Pharmaceutical Design,* 22**,** 4135-4150.

Ahmad, N., Alam, M. K., Shehbaz, A., Khan, A., Mannan, A., Hakim, S. R., Bisht, D. & Owais, M. 2005. Antimicrobial activity of clove oil and its potential in the treatment of vaginal candidiasis. *Journal of Drug Targeting,* 13**,** 555-561.

Akpan, A. & Morgan, R. 2010. Oral candidiasis. *Postgraduate Medical Journal,* 78, 455-459.

Albrecht, A., Felk, A., Pichova, I., Naglik, J. R., Schaller, M., De Groot, P., Maccallum, D., Odds, F. C., Schäfer, W., Klis, F., Monod, M. & Hube, B. 2006. Glycosylphosphatidylinositol-anchored Proteases of *Candida albicans* target proteins necessary for both cellular processes and host-pathogen interactions. *Journal of Biological Chemistry,* 281**,** 688-694.

Almeida, B., Silva, A., Mesquita, A., Sampaio-Marques, B., Rodrigues, F. & Ludovico, P. 2008. Drug-induced apoptosis in yeast. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research,* 1783**,** 1436-1448.

Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., Uno, B. E., Wildeman, E. L., Gonen, T., Rienstra, C. M. & Burke, M. D. 2014. Amphotericin forms an extramembranous and fungicidal sterol sponge. *Nature Chemical Biology,* 10**,** 400-406.

Aoki, W., Kitahara, N., Miura, N., Morisaka, H., Yamamoto, Y., Kuroda, K. & Ueda, M. 2011. Comprehensive characterization of secreted aspartic proteases encoded by a virulence gene family in *Candida albicans*. *The Journal of Biochemistry,* 150**,** 431-438.

Bassetti, M., Taramasso, L., Nicco, E., Molinari, M. P., Mussap, M. & Viscoli, C. 2011. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. *PLOS One,* 6**,** e24198.

Berman, J. & Sudbery, P. E. 2002. *Candida albicans*: A molecular revolution built on lessons from budding yeast. *Nature Reviews Genetics,* 3**,** 918-931.

Bitew, A. & Abebaw, Y. 2018. Vulvovaginal candidiasis: species distribution of *Candida* and their antifungal susceptibility pattern. *BMC Women's Health,* 18.

Bondaryk, M., Kurzątkowski, W. & Staniszewska, M. 2013. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. *Advances in Dermatology and Allergology,* 5**,** 293-301.

Bongomin, F., Gago, S., Oladele, R. & Denning, D. 2017. Global and multi-national prevalence of fungal diseases—estimate precision. *Journal of Fungi,* 3**,** 57.

Bougnoux, M.-E., Kac, G., Aegerter, P., D'enfert, C. & Fagon, J.-Y. 2008. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. *Intensive Care Medicine,* 34**,** 292-299.

Braun, R. J., Zischka, H., Madeo, F., Eisenberg, T., Wissing, S., Büttner, S., Engelhardt, S. M., Büringer, D. & Ueffing, M. 2006. Crucial mitochondrial impairment upon CDC48 mutation in apoptotic Yeast. *Journal of Biological Chemistry,* 281**,** 25757-25767.

Brown, G. D., Denning, D. W., Gow, N. a. R., Levitz, S. M., Netea, M. G. & White, T. C. 2012. Hidden killers: Human fungal infections. *Science Translational Medicine,* 4**,** 165rv13-165rv13.

Butler, M. S., Robertson, A. a. B. & Cooper, M. A. 2014. Natural product and natural product derived drugs in clinical trials. *Natural Product Reports,* 31**,** 1612-1661.

Calandra, T., Roberts, J. A., Antonelli, M., Bassetti, M. & Vincent, J.-L. 2016. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. *Critical Care,* 20.

Calderone, R. A. 2002. Introduction and historical perspectives. In: Calderone RA, editor. *Candida* and Candidiasis. *American Society of Microbiology Press*, Washington, DC, pp: 3-13.

Campoy, S. & Adrio, J. L. 2017. Antifungals. *Biochemical Pharmacology,* 133**,** 86-96.

Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A. & Monk, B. C. 2009. Efflux-mediated antifungal drug resistance. *Clinical Microbiology Reviews,* 22**,** 291-321.

Carmona-Gutierrez, D., Eisenberg, T., Büttner, S., Meisinger, C., Kroemer, G. & Madeo, F. 2010. Apoptosis in yeast: triggers, pathways, subroutines. *Cell Death & Differentiation,* 17**,** 763-773.

Carrasco, H., Raimondi, M., Svetaz, L., Liberto, M. D., Rodriguez, M. V., Espinoza, L., Madrid, A. & Zacchino, S. 2012. Antifungal activity of eugenol analogues. Influence of different substituents and studies on mechanism of action. *Molecules,* 17**,** 1002-1024.

Cassone, A., Mason, R. E. & Kerridge, D. 1981. Lysis of growing yeast-form cells of *Candida albicans* by echinocandin: A cytological study. *Medical Mycology,* 19**,** 97-110.

Cegelski, L., Marshall, G. R., Eldridge, G. R. & Hultgren, S. J. 2008. The biology and future prospects of antivirulence therapies. *Nature Reviews Microbiology,* 6**,** 17-27.

Chaffin, W. L., LóPez-Ribot, J. L., Casanova, M., Gozalbo, D. & MartíNez, J. P. 1998. Cell wall and secreted proteins of *Candida albicans*: Identification, function, and expression. *Microbiology and Molecular Biology Reviews,* 62**,** 130-180.

Chami, N., Bennis, S., Chami, F., Aboussekhra, A. & Remmal, A. 2005. Study of anticandidal activity of carvacrol and eugenol *in vitro* and *in vivo*. *Oral Microbiology and Immunology,* 20**,** 106-111.

Chami, N., Chami, F., Bennis, S., Trouillas, J. & Remmal, A. 2004. Antifungal treatment with carvacrol and eugenol of oral candidiasis in immunosuppressed rats. *Brazilian Journal of Infectious Diseases,* 8.

Chang, Y. L., Yu, S. J., Heitman, J., Wellington, M. & Chen, Y. L. 2017. New facets of antifungal therapy. *Virulence,* 8, 222-236.

Chin, V., Lee, T., Rusliza, B. & Chong, P. 2016. Dissecting *Candida albicans* infection from the perspective of *C. albicans* virulence and omics approaches on host–pathogen interaction: A review. *International Journal of Molecular Sciences,* 17**,** 1643.

Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J. & Chiller, T. M. 2012. Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. *Clinical Infectious Diseases,* 55**,** 1352-1361.

Correia, A., Lermann, U., Teixeira, L., Cerca, F., Botelho, S., Gil Da Costa, R. M., Sampaio, P., Gartner, F., Morschhauser, J., Vilanova, M. & Pais, C. 2010. Limited role of secreted aspartyl proteinases Sap1 to Sap6 in *Candida albicans* virulence and host Immune response in murine hematogenously disseminated candidiasis. *Infection and Immunity,* 78**,** 4839-4849.

da Silva, F. F. M., Monte, F. J. Q., De Lemos, T. L. G., Do Nascimento, P. G. G., De Medeiros Costa, A. K. & De Paiva, L. M. M. 2018. Eugenol derivatives: synthesis, characterization, and evaluation of antibacterial and antioxidant activities. *Chemistry Central Journal,* 12.

Deepa, K., Jeevitha, T. & Michael, A. 2015. *In vitro* evaluation of virulence factors of *Candida* species isolated from oral cavity. *Journal of Microbiology and Antimicrobials,* 7**,** 28-32.

de Oliveira Pereira, F., Mendes, J. M. & de Oliveira Lima, E. 2013. Investigation on mechanism of antifungal activity of eugenol against *Trichophyton rubrum*. *Medical Mycology,* 51**,** 507-513.

De Paula, S. B., Bartelli, T. F., Di Raimo, V., Santos, J. P., Morey, A. T., Bosini, M. A., Nakamura, C. V., Yamauchi, L. M. & Yamada-Ogatta, S. F. 2014. Effect of eugenol on cell surface hydrophobicity, adhesion, and biofilm of *Candida tropicalis* and *Candida*

dubliniensis isolated from oral cavity of HIV-infected patients. *Evidence-Based Complementary and Alternative Medicine,* 2014**,** 1-8.

Denning, D. W. 2003. Echinocandin antifungal drugs. *The Lancet,* 362**,** 1142-1151.

Dhingra, S. & Cramer, R. A. 2017. Regulation of sterol biosynthesis in the human fungal pathogen *Aspergillus fumigatus*: Opportunities for therapeutic development. *Frontiers in Microbiology,* 8.

Dias, D. A., Urban, S. & Roessner, U. 2012. A historical overview of natural products in drug discovery. *Metabolites,* 2**,** 303-336.

Diasio, R. B., Bennett, J. E. & Myers, C. E. 1978. Mode of action of 5-fluorocytosine. *Biochemical Pharmacology,* 27**,** 703-707.

Donlan, R. 2001. Biofilms and device-associated infections. *Emerging Infectious Diseases,* 7**,** 277-281.

Douglas, L. M. & Konopka, J. B. 2014. Fungal membrane organization: The eisosome concept. *Annual Review of Microbiology,* 68**,** 377-393.

Dunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J. & Rogers, P. D. 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical *Candida albicans* isolate. *Eukaryotic Cell,* 7**,** 1180-1190.

Edlind, T. D. & Katiyar, S. K. 2010. Mutational analysis of flucytosine resistance in *Candida glabrata*. *Antimicrobial Agents and Chemotherapy,* 54**,** 4733-4738.

Ekor, M. 2014. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Frontiers in Pharmacology,* 4:177.

Espinel-Ingroff, A. 2008. Mecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos. *Revista Iberoamericana de Micología,* 25**,** 101-106.

Fidel, P. L. 2011. *Candida*-host interactions in HIV disease. *Advances in Dental Research,* 23**,** 45-49.

Garcia-Cuesta, C., Sarrion-Perez, M. G. & Bagan, J. V. 2014. Current treatment of oral candidiasis: A literature review. *Journal of Clinical and Experimental Dentistry*, e576-e582.

Ghannoum, M. A. 2000. Potential role of phospholipases in virulence and fungal pathogenesis. *Clinical Microbiology Reviews,* 13**,** 122-143.

Ghannoum, M. A. & Rice, L. B. 1999. Antifungal Agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clinical Microbiology Reviews,* 12**,** 501-517.

Gourlay, C. W., Du, W. & Ayscough, K. R. 2006. Apoptosis in yeast? mechanisms and benefits to a unicellular organism. *Molecular Microbiology,* 62**,** 1515-1521.

Govender, N. P., Magobo, R. E., Mpembe, R., Mhlanga, M., Matlapeng, P., Corcoran, C., Govind, C., Lowman, W., Senekal, M. & Thomas, J. 2018. *Candida auris* in South Africa, 2012–2016. *Emerging Infectious Diseases,* 24**,** 2036-2040.

Govender, N. P., Patel, J., Magobo, R. E., Naicker, S., Wadula, J., Whitelaw, A., Coovadia, Y., Kularatne, R., Govind, C., Lockhart, S. R. & Zietsman, I. L. 2016. Emergence of azole-resistant *Candida parapsilosis* causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa. *Journal of Antimicrobial Chemotherapy,* 71**,** 1994-2004.

Gow, N. a. R., Brown, A. J. P. & Odds, F. C. 2002. Fungal morphogenesis and host invasion. *Current Opinion in Microbiology,* 5**,** 366-371.

Gow, N. a. R. & Hube, B. 2012. Importance of the *Candida albicans* cell wall during commensalism and infection. *Current Opinion in Microbiology,* 15**,** 406-412.

Grubb, S. E. W., Murdoch, C., Sudbery, P. E., Saville, S. P., Lopez-Ribot, J. L. & Thornhill, M. H. 2008. *Candida albicans*-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. *Infection and Immunity,* 76**,** 4370-4377.

Guaragnella, N., Ždralević, M., Antonacci, L., Passarella, S., Marra, E. & Giannattasio, S. 2012. The role of mitochondria in yeast programmed cell death. *Frontiers in Oncology,* 2.

Gurnani, N., Mehta, D., Gupta, M. & Mehta, B. K. 2014. Natural products: Source of potential drugs. *African Journal of Basic & Applied Sciences,* 6, 171-186.

Halbandge, S. D., Mortale, S. P., Jadhav, A. K., Kharat, K. & Karuppayil, S. M. 2017. Differential sensitivities of various growth modes of *Candida albicans* to sixteen molecules of plant origin. *Journal of Pharmacognosy and Phytochemistry,* 6, 306-318.

Hamill, R. J. 2013. Amphotericin B formulations: A comparative review of efficacy and toxicity. *Drugs,* 73**,** 919-934.

Haque, F., Alfatah, M., Ganesan, K. & Bhattacharyya, M. S. 2016. Inhibitory effect of Sophorolipid on *Candida albicans* biofilm formation and hyphal growth. *Scientific Reports,* 6.

Hata, M., Ishii, Y., Watanabe, E., Uoto, K., Kobayashi, S., Yoshida, K.-I., Otani, T. & Ando, A. 2010. Inhibition of ergosterol synthesis by novel antifungal compounds targeting C-14 reductase. *Medical Mycology,* 48**,** 613-621.

Hawksworth, D. L. 2001. The magnitude of fungal diversity: the 1.5 million species estimate revisited. *Mycological Research,* 105**,** 1422-1432.

He, M., Du, M., Fan, M. & Bian, Z. 2007. In vitro activity of eugenol against *Candida albicans* biofilms. *Mycopathologia,* 163**,** 137-143.

Hernández-Chávez, M., Pérez-García, L., Niño-Vega, G. & Mora-Montes, H. 2017. Fungal strategies to evade the host immune recognition. *Journal of Fungi,* 3**,** 51.

Hipólito, T. M. M., Bastos, G. T. L., Barbosa, T. W. L., Souza, T. B., Coelho, L. F. L., Dias, A. L. T., Rodríguez, I. C., Dos Santos, M. H., Dias, D. F., Franco, L. L. & Carvalho, D. T. 2018. Synthesis, activity, and docking studies of eugenol-based glucosides as new agents against *Candida* sp. *Chemical Biology & Drug Design,* 92**,** 1514-1524.

Hube, B., Rüchel, R., Monod, M., Sanglard, D. & Odds, F. C. 1998. Functional aspects of secreted *Candida* proteinases. *Aspartic Proteinases*. Springer US.

Hube, B., Stehr, F., Bossenz, M., Mazur, A., Kretschmar, M. & Schäfer, W. 2000. Secreted lipases of *Candida albicans*: cloning, characterisation and expression analysis of a new gene family with at least ten members. *Archives of Microbiology,* 174**,** 362-374.

Huh, G.-H., Damsz, B., Matsumoto, T. K., Reddy, M. P., Rus, A. M., Ibeas, J. I., Narasimhan, M. L., Bressan, R. A. & Hasegawa, P. M. 2002. Salt causes ion disequilibrium-induced programmed cell death in yeast and plants. *The Plant Journal,* 29**,** 649-659.

Igney, F. H. & Krammer, P. H. 2002. Death and anti-death: tumour resistance to apoptosis. *Nature Reviews Cancer,* 2**,** 277-288.

Ilkit, M. & Guzel, A. B. 2011. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. *Critical Reviews in Microbiology,* 37**,** 250-261.

Jabra-Rizk, M. A., Kong, E. F., Tsui, C., Nguyen, M. H., Clancy, C. J., Fidel, P. L. & Noverr, M. 2016. *Candida albicans* pathogenesis: Fitting within the host-microbe damage response framework. *Infection and Immunity,* 84**,** 2724-2739.

Jacobsen, I. D., Wilson, D., Wächtler, B., Brunke, S., Naglik, J. R. & Hube, B. 2012. *Candida albicans* dimorphism as a therapeutic target. *Expert Review of Anti-infective Therapy,* 10**,** 85-93.

Jia, C., Zhang, J., Yu, L., Wang, C., Yang, Y., Rong, X., Xu, K. & Chu, M. 2019. Antifungal activity of Coumarin against *Candida albicans* is related to apoptosis. *Frontiers in Cellular and Infection Microbiology,* 8.

Jones, T., Federspiel, N. A., Chibana, H., Dungan, J., Kalman, S., Magee, B. B., Newport, G., Thorstenson, Y. R., Agabian, N., Magee, P. T., Davis, R. W. & Scherer, S. 2004. The diploid genome sequence of *Candida albicans*. *Proceedings of the National Academy of Sciences,* 101**,** 7329-7334.

Kabir, M. A., Hussain, M. A. & Ahmad, Z. 2012. *Candida albicans*: A model organism for studying fungal pathogens. *ISRN Microbiology,* 2012**,** 1-15.

Kanafani, Z. A. & Perfect, J. R. 2008. Resistance to antifungal agents: mechanisms and clinical impact. *Clinical Infectious Diseases,* 46**,** 120-128.

Karkowska-Kuleta, J., Rapala-Kozik, M. & Kozik, A. 2009. Fungi pathogenic to humans: molecular bases of virulence of *Candida albicans, Cryptococcus neoformans* and *Aspergillus fumigatus*. *Acta Biochimica Polonica,* 56.

Kaufman, D. A., Coggins, S. A., Zanelli, S. A. & Weitkamp, J.-H. 2017. Congenital cutaneous candidiasis: Prompt systemic treatment is associated with improved outcomes in neonates. *Clinical Infectious Diseases,* 64**,** 1387-1395.

Kett, D. H., Azoulay, E., Echeverria, P. M. & Vincent, J.-L. 2011. *Candida* bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. *Critical Care Medicine,* 39**,** 665-670.

Khameneh, B., Iranshahy, M., Soheili, V. & Fazly Bazzaz, B. S. 2019. Review on plant antimicrobials: a mechanistic viewpoint. *Antimicrobial Resistance & Infection Control,* 8.

Khan, A., Ahmad, A., Khan, L. A. & Manzoor, N. 2014. *Ocimum sanctum* (L.) essential oil and its lead molecules induce apoptosis in *Candida albicans*. *Research in Microbiology,* 165**,** 411-419.

Khan, M. S., Ahmad, I. & Cameotra, S. 2013. Phenyl aldehyde and propanoids exert multiple sites of action towards cell membrane and cell wall targeting ergosterol in *Candida albicans*. *AMB Express,* 3**,** 54.

Khan, M. S. A., Ahmad, I., Aqil, F., Owais, M., Shahid, M. & Musarrat, J. 2010. Virulence and pathogenicity of fungal pathogens with special reference to *Candida albicans*. *Combating Fungal Infections*. Springer Berlin Heidelberg. pp: 21-45.

Khan, M. S. A., Malik, A. & Ahmad, I. 2012. Anti-*candidal* activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of *Candida albicans*. *Medical Mycology,* 50**,** 33-42.

King, D. A., Hannum, D. M., Qi, J.-S. & Hurst, J. K. 2004. HOCl-mediated cell death and metabolic dysfunction in the yeast *Saccharomyces cerevisiae*. *Archives of Biochemistry and Biophysics,* 423**,** 170-181.

Kontoyiannis, D. P. & Lewis, R. E. 2002. Antifungal drug resistance of pathogenic fungi. *The Lancet,* 359**,** 1135-1144.

Kreusch, A. & Karstaedt, A. S. 2013. Candidemia among adults in Soweto, South Africa, 1990–2007. *International Journal of Infectious Diseases,* 17**,** e621-e623.

Kullberg, B. J. & Arendrup, M. C. 2015. Invasive candidiasis. *New England Journal of Medicine,* 373**,** 1445-1456.

Kumar, A., Ekavali, Chopra, K., Mukherjee, M., Pottabathini, R. & Dhull, D. K. 2015. Current knowledge and pharmacological profile of berberine: An update. *European Journal of Pharmacology,* 761**,** 288-297.

Nigam, P. K. 2015. Antifungal drugs and resistance: Current concepts. *Our Dermatology Online,* 6**,** 212-221.

Kutlubay, Z., Yardımcı, G., Kantarcıoğlu, A. S. & Serdaroğlu, S. 2017. Acral manifestations of fungal infections. *Clinics in Dermatology,* 35**,** 28-39.

Langenbeck, B. 1839. Auffinggung von Pilzen aus der Schleimhaut der Speiserohne einer Typhus-Leiche. Neue Not Geb Natur-uHelik. *Froriep,* 12, 145-147.

Latifah-Munirah, B., Himratul-Aznita, W. H. & Mohd Zain, N. 2015. Eugenol, an essential oil of clove, causes disruption to the cell wall of *Candida albicans* (ATCC 14053). *Frontiers in Life Science,* 8**,** 231-240.

Leidich, S. D., Ibrahim, A. S., Fu, Y., Koul, A., Jessup, C., Vitullo, J., Fonzi, W., Mirbod, F., Nakashima, S., Nozawa, Y. & Ghannoum, M. A. 1998. Cloning and disruption of

caPLB1, a phospholipase B gene involved in the pathogenicity of *Candida albicans*. *Journal of Biological Chemistry,* 273**,** 26078-26086.

Leroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B. & Lortholary, O. 2009. Epidemiology, management, and risk factors for death of invasive *Candida* infections in critical care: A multicenter, prospective, observational study in France (2005–2006). *Critical Care Medicine,* 37**,** 1612-1618.

Lim, C. S. Y., Rosli, R., Seow, H. F. & Chong, P. P. 2012. *Candida* and invasive candidiasis: back to basics. *European Journal of Clinical Microbiology & Infectious Diseases,* 31**,** 21-31.

Liu, Y. & Filler, S. G. 2011. *Candida albicans* Als3, a Multifunctional adhesin and invasin. *Eukaryotic Cell,* 10**,** 168-173.

Lone, S. A. & Ahmad, A. 2019. *Candida auris* —the growing menace to global health. *Mycoses,* 62**,** 620-637.

Ludovico, P., Rodrigues, F., Almeida, A., Silva, M. T., Barrientos, A. & Côrte-Real, M. 2002. Cytochrome c release and mitochondria involvement in programmed cell death induced by acetic acid in *Saccharomyces cerevisiae*. *Molecular Biology of the Cell,* 13**,** 2598-2606.

Lv, Q.-Z., Yan, L. & Jiang, Y.-Y. 2016. The synthesis, regulation, and functions of sterols in *Candida albicans*: Well-known but still lots to learn. *Virulence,* 7**,** 649-659.

Madeo, F., Engelhardt, S., Herker, E., Lehmann, N., Maldener, C., Proksch, A., Wissing, S. & Fröhlich, K.-U. 2002. Apoptosis in yeast: a new model system with applications in cell biology and medicine. *Current Genetics,* 41**,** 208-216.

Madeo, F., Fröhlich, E. & Fröhlich, K.-U. 1997. A yeast mutant showing diagnostic markers of early and late apoptosis. *The Journal of Cell Biology,* 139**,** 729-734.

Madeo, F., Fröhlich, E., Ligr, M., Grey, M., Sigrist, S. J., Wolf, D. H. & Fröhlich, K.-U. 1999. Oxygen stress: A regulator of apoptosis in yeast. *The Journal of Cell Biology,* 145**,** 757-767.

Madeo, F., Herker, E., Wissing, S., Jungwirth, H., Eisenberg, T. & Fröhlich, K.-U. 2004. Apoptosis in yeast. *Current Opinion in Microbiology,* 7**,** 655-660.

Maertens, J. A. 2004. History of the development of azole derivatives. *Clinical Microbiology and Infection,* 10**,** 1-10.

Makhado, N. A., Ismail, F., Dangor, Y., Chephe, T. J. H., Hoosen, A. A. & Nchabeleng, M. 2014. Antifungal susceptibility profile of yeast isolates from sterile sites at a tertiary hospital in South Africa. *Southern African Journal of Infectious Diseases,* 29**,** 97-100.

Mancera, E., Frazer, C., Porman, A. M., Ruiz-Castro, S., Johnson, A. D. & Bennett, R. J. 2019. Genetic modification of closely related *Candida* Species. *Frontiers in Microbiology,* 10.

Mansur, A. T., Aydingoz, I. E. & Artunkal, S. 2012. Facial *Candida* folliculitis: possible role of sexual contact. *Mycoses***,** 55, e20-2.

Marr, K. A., White, T. C., Van Burik, J. a. H. & Bowden, R. A. 1997. Development of fluconazole resistance in *Candida albicans* causing disseminated infection in a patient undergoing marrow transplantation. *Clinical Infectious Diseases,* 25**,** 908-910.

Marriott, D. J. E., Playford, E. G., Chen, S., Slavin, M., Nguyen, Q., Ellis, D. & Sorrell, T. C. 2009. Determinants of mortality in non-neutropenic ICU patients with candidaemia. *Critical Care,* 13**,** R115.

Mavor, A., Thewes, S. & Hube, B. 2005. Systemic fungal infections caused by *Candida* Species: epidemiology, infection process and virulence attributes. *Current Drug Targets,* 6**,** 863-874.

Mayer, L. 1862. Die Pflanzlichen parasiten der weiblichen Sexualorgane in ihrer praktischen Bedeutung. *Mschr Geburtsch Frauenkrank,* 20, 2-16.

Mayer, F. L., Wilson, D. & Hube, B. 2013. *Candida albicans* pathogenicity mechanisms. *Virulence,* 4**,** 119-128.

Mazzoni, C. & Falcone, C. 2008. Caspase-dependent apoptosis in yeast. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research,* 1783**,** 1320-1327.

Metin, A., Genç Dilek, N. & Gunes Bilgili, S. 2018. Recurrent candidal intertrigo: challenges and solutions. *Clinical, Cosmetic and Investigational Dermatology,* Volume 11**,** 175-185.

Mnge, P., Okeleye, B. I., Vasaikar, S. D. & Apalata, T. 2017. Species distribution and antifungal susceptibility patterns of *Candida* isolates from a public tertiary teaching hospital in the Eastern Cape Province, South Africa. *Brazilian Journal of Medical and Biological Research,* 50.

Modjtahedi, N., Giordanetto, F., Madeo, F. & Kroemer, G. 2006. Apoptosis-inducing factor: vital and lethal. *Trends in Cell Biology,* 16**,** 264-272.

Morace, G., Perdoni, F. & Borghi, E. 2014. Antifungal drug resistance in *Candida* species. *Journal of Global Antimicrobial Resistance,* 2**,** 254-259.

Morio, F., Jensen, R. H., Le Pape, P. & Arendrup, M. C. 2017. Molecular basis of antifungal drug resistance in yeasts. *International Journal of Antimicrobial Agents,* 50**,** 599-606.

Morio, F., Loge, C., Besse, B., Hennequin, C. & Le Pape, P. 2010. Screening for amino acid substitutions in the *Candida albicans* Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. *Diagnostic Microbiology and Infectious Disease,* 66**,** 373-384.

Morschhäuser, J. 2002. The genetic basis of fluconazole resistance development *in Candida albicans*. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease,* 1587**,** 240-248.

Murciano, C., Moyes, D. L., Runglall, M., Tobouti, P., Islam, A., Hoyer, L. L. & Naglik, J. R. 2012. Evaluation of the role of *Candida albicans* agglutinin-like sequence (Als) proteins in human oral epithelial cell interactions. *PLoS ONE,* 7**,** e33362.

Naglik, J. R., Challacombe, S. J. & Hube, B. 2003. *Candida albicans* Secreted aspartyl proteinases in virulence and pathogenesis. *Microbiology and Molecular Biology Reviews,* 67**,** 400-428.

Naglik, J. R., Moyes, D., Makwana, J., Kanzaria, P., Tsichlaki, E., Weindl, G., Tappuni, A. R., Rodgers, C. A., Woodman, A. J., Challacombe, S. J., Schaller, M. & Hube, B. 2008. Quantitative expression of the *Candida albicans* secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. *Microbiology,* 154**,** 3266-3280.

Naglik, J. R., Moyes, D. L., Wächtler, B. & Hube, B. 2011. *Candida albicans* interactions with epithelial cells and mucosal immunity. *Microbes and Infection,* 13**,** 963-976.

Naicker, S. D., Govender, N., Patel, J., Zietsman, I. L., Wadula, J., Coovadia, Y., Kularatne, R., Seetharam, S. & Govender, N. P. 2016. Comparison of species-level identification and antifungal susceptibility results from diagnostic and reference laboratories for bloodstream *Candida* surveillance isolates, South Africa, 2009–2010. *Medical Mycology,* 54**,** 816-824.

Newman, D. J. & Cragg, G. M. 2016. Natural products as sources of new drugs from 1981 to 2014. *Journal of Natural Products,* 79**,** 629-661.

Ngo, H. X., Garneau-Tsodikova, S. & Green, K. D. 2016. A complex game of hide and seek: the search for new antifungals. *Medicinal Chemistry Communications,* 7**,** 1285-1306.

Nobile, Clarissa j., Fox, Emily p., Nett, Jeniel e., Sorrells, Trevor r., Mitrovich, Quinn m., Hernday, Aaron d., Tuch, Brian b., Andes, David r. & Johnson, Alexander d. 2012. A recently evolved transcriptional network controls biofilm development in *Candida albicans*. *Cell,* 148**,** 126-138.

Nobile, C. J. & Johnson, A. D. 2015. *Candida albicans* biofilms and human disease. *Annual Review of Microbiology,* 69**,** 71-92.

Nobile, C. J., Schneider, H. A., Nett, J. E., Sheppard, D. C., Filler, S. G., Andes, D. R. & Mitchell, A. P. 2008. Complementary adhesin function in *C. albicans* biofilm formation. *Current Biology,* 18**,** 1017-1024.

Noble, S. M., Gianetti, B. A. & Witchley, J. N. 2017. *Candida albicans* cell-type switching and functional plasticity in the mammalian host. *Nature Reviews Microbiology,* 15**,** 96-108.

Odds, F. C. 2009. In *Candida albicans*, resistance to flucytosine and terbinafine is linked to MAT locus homozygosity and multilocus sequence typing clade 1. *FEMS Yeast Research,* 9**,** 1091-1101.

Olea, A., Bravo, A., Martínez, R., Thomas, M., Sedan, C., Espinoza, L., Zambrano, E., Carvajal, D., Silva-Moreno, E. & Carrasco, H. 2019. Antifungal activity of eugenol derivatives against *Botrytis Cinerea*. *Molecules,* 24**,** 1239.

Osborne, C. S., Leitner, I., Hofbauer, B., Fielding, C. A., Favre, B. & Ryder, N. S. 2006. Biological, biochemical, and molecular characterization of a new clinical *Trichophyton rubrum* isolate resistant to terbinafine. *Antimicrobial Agents and Chemotherapy,* 50**,** 2234-2236.

Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C. & Rex, J. H. 2010. An insight into the antifungal pipeline: Selected new molecules and beyond. *Nature Reviews Drug Discovery,* 9**,** 719-727.

Patricia, B. G., Ana, I. M., Manuel, D. N. J. J., Amparo, L. L., Maria, M. R. J., Angeles, G. N. M. & Jose, L. R. M. 2016. Esophageal candidiasis in an immunocompetent girl with chronic anaemia. *Journal of Gastroenterology and Digestive Diseases,* 1, 1-24.

Pawar, P. R., Pawar, V. A. & Aute, R. A. 2014. Role of extracellular hydrolytic enzymes in *Candida albicans* virulence. *International journal of pharmaceutical sciences review and research,* 2, pp:1521-1532.

Perfect, J. R. 2017. The antifungal pipeline: a reality check. *Nature Reviews Drug Discovery,* 16**,** 603-616.

Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. *Drug Resistance Updates,* 10**,** 121-130.

Perlin, D. S. 2011. Current perspectives on echinocandin class drugs. *Future Microbiology,* 6**,** 441-457.

Perlin, D. S., Rautemaa-Richardson, R. & Alastruey-Izquierdo, A. 2017. The global problem of antifungal resistance: prevalence, mechanisms, and management. *The Lancet Infectious Diseases,* 17**,** e383-e392.

Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P. & Horn, D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. *Diagnostic Microbiology and Infectious Disease,* 74**,** 323-331.

Pfaller, M. A. & Diekema, D. J. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. *Clinical Microbiology Reviews,* 20**,** 133-163.

Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N. & Castanheira, M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: Application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. *Journal of Clinical Microbiology,* 51**,** 2571-2581.

Phan, Q. T., Myers, C. L., Fu, Y., Sheppard, D. C., Yeaman, M. R., Welch, W. H., Ibrahim, A. S., Edwards, J. E. & Filler, S. G. 2007. Als3 is a *Candida albicans* invasin that binds to cadherins and induces endocytosis by host cells. *PLOS Biology,* 5**,** e64.

Phillips, A. J., Sudbery, I. & Ramsdale, M. 2003. Apoptosis induced by environmental stresses and amphotericin B in *Candida albicans*. *Proceedings of the National Academy of Sciences,* 100**,** 14327-14332.

Piccione, D., Mirabelli, S., Minto, N. & Bouklas, T. 2019. Difficult but not impossible: in search of an anti-*Candida* vaccine. *Current Tropical Medicine Reports,* 6**,** 42-49.

Pierce, C. G. & Lopez-Ribot, J. L. 2013. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. *Expert Opinion on Drug Discovery,* 8**,** 1117-1126.

Pinto, E., Vale-Silva, L., Cavaleiro, C. & Salgueiro, L. 2009. Antifungal activity of the clove essential oil from Syzygium aromaticum on *Candida, Aspergillus* and *dermatophyte* species. *Journal of Medical Microbiology,* 58**,** 1454-1462.

Polak, A. & Scholer, H. J. 1975. Mode of action of 5-fluorocytosine and mechanisms of resistance. *Chemotherapy,* 21**,** 113-130.

Prasad, R., De Wergifosse, P., Goffeau, A. & Balzi, E. 1995. Molecular cloning and characterization of a novel gene of *Candida albicans*, CDR1, conferring multiple resistance to drugs and antifungals. *Current Genetics,* 27**,** 320-329.

Prasad, R. & Kapoor, K. 2004. Multidrug resistance in yeast *Candida*. *International Review of Cytology,* 242, 215-248.

Price, M. F., Wilkinson, I. D. & Gentry, L. O. 1982. Plate method for detection of phospholipase activity in *Candida albicans*. *Medical Mycology,* 20**,** 7-14.

Ramage, G., Wickers, B. L. & Lopez-Ribot, J. L. 2001. Biofilms of *Candida albicans* and their associated resistance to antifungal agents. *American Clinical Laboratory,* 20, 42-44.

Raut, J. S., Shinde, R. B., Chauhan, N. M. & Mohan Karuppayil, S. 2013. Terpenoids of plant origin inhibit morphogenesis, adhesion, and biofilm formation by *Candida albicans*. *Biofouling,* 29**,** 87-96.

Rhodus, N. L. 2012. Treatment of oral candidiasis. *Northwest Dentistry,* 91, 32–33.

Rigopoulos, D., Gregoriou, S., Belyayeva, Y., Larios, G., Gkouvi, A. & Katsambas, A. 2009. Acute paronychia caused by lapatinib therapy. *Clinical and Experimental Dermatology,* 34**,** 94-95.

Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D. & Cowen, L. E. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. *PLoS Pathogens,* 7**,** e1002257.

Robin, C. 1853. Natural history of parasitic plants which grow on man and on living animals, J.-B. Ballière.

Roemer, T. & Krysan, D. J. 2014. Antifungal drug development: challenges, unmet clinical needs, and new approaches. *Cold Spring Harbor perspectives in medicine,* 4, a019703.

Römling, U. & Balsalobre, C. 2012. Biofilm infections, their resilience to therapy and innovative treatment strategies. *Journal of Internal Medicine,* 272**,** 541-561.

Sachin, C. D., Ruchi, K. & Santosh, S. 2012. *In vitro* evaluation of proteinase, phospholipase and haemolysin activities of *Candida* species isolated from clinical specimens. *International Journal of Medicine and Biomedical Research,* 1**,** 153-157.

Salerno, C., Pascale, M., Contaldo, M., Esposito, V., Busciolano, M., Milillo, L., Guida, A., Petruzzi, M. & Serpico, R. 2011. *Candida*-associated denture stomatitis. *Medicina Oral Patología Oral y Cirugia Bucal***,** e139-e143.

Sanglard, D., Ischer, F., Parkinson, T., Falconer, D. & Bille, J. 2003. *Candida albicans* mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. *Antimicrobial Agents and Chemotherapy,* 47**,** 2404-2412.

Sardi, J. C. O., Mendes Giannini, M. J. S., Bernardi, T., Scorzoni, L. & Fusco-Almeida, A. M. 2013. *Candida* species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. *Journal of Medical Microbiology,* 62**,** 10-24.

Saville, S. P., Lazzell, A. L., Monteagudo, C. & Lopez-Ribot, J. L. 2003. Engineered control of cell morphology *in vivo* reveals distinct roles for yeast and filamentous forms of *Candida albicans* during infection. *Eukaryotic Cell,* 2**,** 1053-1060.

Schaller, M., Borelli, C., Korting, H. C. & Hube, B. 2005. Hydrolytic enzymes as virulence factors of *Candida albicans*. *Mycoses,* 48**,** 365-377.

Selmecki, A. 2006. Aneuploidy and isochromosome formation in drug-resistant *Candida albicans*. *Science,* 313**,** 367-370.

Shapiro, R. S., Robbins, N. & Cowen, L. E. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. *Microbiology and Molecular Biology Reviews,* 75**,** 213-267.

Shareck, J. & Belhumeur, P. 2011. Modulation of morphogenesis in *Candida albicans* by various small molecules. *Eukaryotic Cell,* 10**,** 1004-1012.

Shreaz, S., Bhatia, R., Khan, N., Muralidhar, S., F. Basir, S., Manzoor, N. & Ahmad Khan, L. 2011. Exposure of *Candida* to p-anisaldehyde inhibits its growth and ergosterol biosynthesis. *The Journal of General and Applied Microbiology,* 57**,** 129-136.

Shu, Y.-Z. 1998. Recent natural products based drug development: A pharmaceutical industry perspective. *Journal of Natural Products,* 61**,** 1053-1071.

Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B. & Fridkin, S. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009–2010. *Infection Control & Hospital Epidemiology,* 34**,** 1-14.

Silva, R. D., Sotoca, R., Johansson, B., Ludovico, P., Sansonetty, F., Silva, M. T., Peinado, J. M. & Côrte-Real, M. 2005. Hyperosmotic stress induces metacaspase- and mitochondria-dependent apoptosis in *Saccharomyces cerevisiae*. *Molecular Microbiology,* 58**,** 824-834.

Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W. & Azeredo, J. 2011. Adherence and biofilm formation of non-*Candida albicans Candida* species. *Trends in Microbiology,* 19**,** 241-247.

Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W. & Azeredo, J. 2012. *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. *FEMS Microbiology Reviews,* 36**,** 288-305.

Silver, P. M., Oliver, B. G. & White, T. C. 2004. Role of *Candida albicans* transcription factor Upc2p in drug resistance and sterol metabolism. *Eukaryotic Cell,* 3**,** 1391-1397.

Simon, H. U., Haj-Yehia, A. & Levi-Schaffer, F. 2000. Role of reactive oxygen species (ROS) in apoptosis induction. *Apoptosis,* 5**,** 415-418.

Sokol-Anderson, M. L., Brajtburg, J. & Medoff, G. 1986. Amphotericin B-induced oxidative damage and killing of *Candida albicans*. *Journal of Infectious Diseases,* 154**,** 76-83.

Spampinato, C. & Leonardi, D. 2013. *Candida Infections*, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. *BioMed Research International,* 2013**,** 1-13.

Staib, P. & Morschhäuser, J. 2007. Chlamydospore formation in *Candida albicans* and *Candida dubliniensis*? an enigmatic developmental programme. *Mycoses,* 50**,** 1-12.

Staniszewska, M., Bondaryk, M., Siennicka, K., Pilat, J., Schaller, M. & Kurzatkowski, W. 2012. Role of aspartic proteinases in *Candida albicans* virulence. Part I. Substrate specifity of aspartic proteinases and *Candida albicans* pathogenesis. *Postępymikrobiologii,* 51(2) p:72.

Stehr, F., Felk, A., Gacser, A., Kretschmar, M., Mahns, B., Neuber, K., Hube, B. & Schafer, W. 2004. Expression analysis of the lipase gene family during experimental infections and in-patient samples. *FEMS Yeast Research,* 4**,** 401-408.

Stehr, F., Kretschmar, M., Kröger, C., Hube, B. & Schäfer, W. 2003. Microbial lipases as virulence factors. *Journal of Molecular Catalysis B: Enzymatic,* 22**,** 347-355.

St-Germain, G., Laverdière, M., Pelletier, R., René, P., Bourgault, A.-M., Lemieux, C. & Libman, M. 2008. Epidemiology and antifungal susceptibility of blood stream *Candida* isolates in quebec: Report on 453 cases between 2003 and 2005. *Canadian Journal of Infectious Diseases and Medical Microbiology,* 19**,** 55-62.

Stratton, C. F., Newman, D. J. & Tan, D. S. 2015. Cheminformatic comparison of approved drugs from natural product versus synthetic origins. *Bioorganic & Medicinal Chemistry Letters,* 25**,** 4802-4807.

Wilkinson, J. S. 1849. Some remarks upon the development of epiphytes. *The Lancet,* 54**,** 448-451.

Sudbery, P., Gow, N. & Berman, J. 2004. The distinct morphogenic states of *Candida albicans*. *Trends in Microbiology,* 12**,** 317-324.

Sundstrom, P. 2002. Reevaluation of the role of HWP1 in systemic candidiasis by use of *Candida albicans* strains with selectable marker URA3 targeted to the ENO1 locus. *Infection and Immunity,* 70**,** 3281-3283.

Sundstrom, P., Balish, E. & Allen, Carl m. 2002. Essential role of the *Candida albicans* transglutaminase substrate, hyphal wall protein 1, in lethal or oesophageal candidiasis in immunodeficient mice. *The Journal of Infectious Diseases,* 185**,** 521-530.

Taylor, B. N., Hannemann, H., Sehnal, M., Biesemeier, A., Schweizer, A., Rollinghoff, M. & Schroppel, K. 2005. Induction of SAP7 correlates with virulence in an intravenous infection model of candidiasis but not in a vaginal infection model in mice. *Infection and Immunity,* 73**,** 7061-7063.

Terézhalmy, G. T. & Huber, M. A. 2011. Oropharyngeal candidiasis: etiology, epidemiology, clinical manifestations, diagnosis, and treatment. *dentalcare.com*. pp: 1-16.

Theiss, S., Ishdorj, G., Brenot, A., Kretschmar, M., Lan, C.-Y., Nichterlein, T., Hacker, J., Nigam, S., Agabian, N. & Köhler, G. A. 2006. Inactivation of the phospholipase B gene PLB5 in wild-type *Candida albicans* reduces cell-associated phospholipase A2 activity and attenuates virulence. *International Journal of Medical Microbiology,* 296**,** 405-420.

Thompson, D. S., Carlisle, P. L. & Kadosh, D. 2011. Coevolution of morphology and virulence in *Candida* Species. *Eukaryotic Cell,* 10**,** 1173-1182.

Tronchin, G., Pihet, M., Lopes-Bezerra, L. M. & Bouchara, J.-P. 2008. Adherence mechanisms in human pathogenic fungi. *Medical Mycology,* 46**,** 749-772.

Tsai, P.-W., Chen, Y.-T., Hsu, P.-C. & Lan, C.-Y. 2013. Study of *Candida albicans* and its interactions with the host: A mini review. *BioMedicine,* 3**,** 51-64.

Turner, S. A. & Butler, G. 2014. The *Candida* pathogenic species complex. *Cold Spring Harbor Perspectives in Medicine,* 4**,** a019778-a019778.

Tyc, K. M., Kühn, C., Wilson, D. & Klipp, E. 2014. Assessing the advantage of morphological changes in *Candida albicans*: a game theoretical study. *Frontiers in Microbiology,* 5.

Vandeputte, P., Ferrari, S. & Coste, A. T. 2012. Antifungal resistance and new strategies to control fungal infections. *International Journal of Microbiology,* 2012**,** 1-26.

Vazquez, J. A. & Sobel, J. D. 2011. Candidiasis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, eds. *Essentials of Clinical Mycology*, New York: Springer; p:167-206.

Vediyappan, G., Dumontet, V., Pelissier, F. & D'enfert, C. 2013. Gymnemic acids inhibit hyphal growth and virulence in *Candida albicans*. *PLOS One,* 8**,** e74189.

Vermes, A. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. *Journal of Antimicrobial Chemotherapy*, 46**,** 171-179.

Vila, T., Romo, J. A., Pierce, C. G., Mchardy, S. F., Saville, S. P. & Lopez-Ribot, J. L. 2017. Targeting *Candida albicans* filamentation for antifungal drug development. *Virulence,* 8**,** 150-158.

Wadskog, I., Maldener, C., Proksch, A., Madeo, F. & Adler, L. 2004. Yeast lacking the SRO7/SOP1-encoded tumor suppressor homologue show increased susceptibility to apoptosis-like cell death on exposure to NaCl stress. *Molecular Biology of the Cell,* 15**,** 1436-1444.

Wang, H., Kong, F., Sorrell, T. C., Wang, B., Mcnicholas, P., Pantarat, N., Ellis, D., Xiao, M., Widmer, F. & Chen, S. C. A. 2009. Rapid detection of ERG11 gene mutations in clinical *Candida albicans* isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. *BMC Microbiology,* 9**,** 167.

Wang, J. M., Bennett, R. J. & Anderson, M. Z. 2018. The genome of the human pathogen *Candida albicans* is shaped by mutation and cryptic sexual recombination. *mBio,* 9.

Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K. & Hata, K. 2012. E1210, a new broad-spectrum antifungal, suppresses *Candida albicans* hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. *Antimicrobial Agents and Chemotherapy,* 56**,** 960-971.

Wenzel, R. P. & Gennings, C. 2005. Bloodstream infections due to *Candida* species in the intensive care unit: Identifying especially high-risk patients to determine prevention strategies. *Clinical Infectious Diseases,* 41**,** S389-S393.

Williams, D. & Lewis, M. 2011. Pathogenesis and treatment of oral candidosis. *Journal of Oral Microbiology,* 3**,** 5771.

Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K. & Beney, J. 2002. The direct cost and incidence of systemic fungal infections. *Value in Health,* 5**,** 26-34.

Winner, H. I. & R, Hurley. 1954. *Candida albicans*. Boston, Mass., Little, Brown and Company.

Wu, X.-Z., Chang, W.-Q., Cheng, A.-X., Sun, L.-M. & Lou, H.-X. 2010. Plagiochin E, an antifungal active macrocyclic bis(bibenzyl), induced apoptosis in *Candida albicans* through a metacaspase-dependent apoptotic pathway. *Biochimica et Biophysica Acta (BBA) - General Subjects,* 1800**,** 439-447.

Yang, H., Ren, Q. & Zhang, Z. 2008. Cleavage of Mcd1 by caspase-like protease Esp1 promotes apoptosis in budding yeast. *Molecular Biology of the Cell,* 19**,** 2127-2134.

Yapar, N. 2014. Epidemiology and risk factors for invasive candidiasis. *Therapeutics and Clinical Risk Management***,** 95.

Zeng, X., Zhang, Y., Zhang, T., Xue, Y., Xu, H. & An, R. 2018. Risk factors of vulvovaginal candidiasis among women of reproductive age in Xi'an: A cross-sectional study. *BioMed Research International,* 2018**,** 1-8.

Zeng, Y.-B., Qian, Y.-S., Ma, L. & Gu, H.-N. 2007. Genome-wide expression profiling of the response to terbinafine in *Candida albicans* using a cDNA microarray analysis. *Chinese Medical Journal,* 120**,** 807-813.

Zhang, P., Zhang, E., Xiao, M., Chen, C. & Xu, W. 2013. Study of anti-inflammatory activities of α-d-glucosylated eugenol. *Archives of Pharmacal Research,* 36**,** 109-115.

Zhu, W. & Filler, S. G. 2010. Interactions of *Candida albicans* with epithelial cells. *Cellular Microbiology,* 12**,** 273-282.

Zordan, R. & Cormack, B. 2012. Adhesins on opportunistic fungal pathogens. In: Calderone RA, Clancy CJ, ed. *Candida* and Candidiasis: *American Society of Microbiology Press*, Washington, DC, pp: 243-259.

Zischka, H., Braun, R. J., Marantidis, E. P., Büringer, D., Bornhövd, C., Hauck, S. M., Demmer, O., Gloeckner, C. J., Reichert, A. S., Madeo, F. & Ueffing, M. 2006. Differential Analysis of *Saccharomyces cerevisiae* mitochondria by free flow electrophoresis. *Molecular & Cellular Proteomics,* 5**,** 2185-2200.

Zotchev, S. 2003. Polyene macrolide antibiotics and their applications in human therapy. *Current Medicinal Chemistry,* 10**,** 211-223.